Patents by Inventor David Kass

David Kass has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20200289519
    Abstract: The disclosure provides methods, treatments and materials for enhancing the effect of an adenosine A2 receptor agonist in the treatment, mitigation or prophylaxis of a disease or condition characterized by inotropic and/or lusitropic dysfunction, and/or enhancing adenosine A2 receptor function in the treatment, mitigation or prophylaxis of a disease or condition characterized by impaired adenosine A2 receptor function, comprising administration of an effective amount of a PDE1 inhibitor to a patient in need thereof, for example a patient suffering from heart failure.
    Type: Application
    Filed: June 3, 2020
    Publication date: September 17, 2020
    Inventors: David KASS, Toru HASHIMOTO, Lawrence P. WENNOGLE, Joseph HENDRICK, Robert DAVIS
  • Patent number: 10729337
    Abstract: The present application relates to systems and methods for non-invasively determining at least one of left ventricular end diastolic pressure (LVEDP) or pulmonary capillary wedge pressure (PCWP) in a subject's heart, comprising: receiving, by a computer, a plurality of signals from a plurality of non-invasive sensors that measure a plurality of physiological effects that are correlated with functioning of said subject's heart, said plurality of physiological effects including at least one signal correlated with left ventricular blood pressure and at least one signal correlated with timing of heartbeat cycles of said subject's heart; training a machine learning model on said computer using said plurality of signals for periods of time in which said plurality of signals were being generated during a heart failure event of said subject's heart; determining said LVEDP or PCWP using said machine learning model at a time subsequent to said training and subsequent to said heart failure event.
    Type: Grant
    Filed: May 5, 2016
    Date of Patent: August 4, 2020
    Assignees: The Johns Hopkins University, Boston Scientific Scimed Inc.
    Inventors: Qian Liu, Nichaluk Leartprapun, Jackline Wanjala, Soumyadipta Acharya, Andrew Bicek, Viachaslau Barodka, Umang Anand, Majd Alghatrif, David Kass, B. Westbrook Bernier, Chao-Wei Hwang, Peter Johnston, Trent Langston
  • Publication number: 20200147381
    Abstract: The invention provides methods related to improving heart function.
    Type: Application
    Filed: November 19, 2019
    Publication date: May 14, 2020
    Inventors: David KASS, Gordon TOMASELLI, Jonathan KIRK
  • Publication number: 20200149062
    Abstract: Provided herein are engineered TSC2 polypeptides, and nucleic acid sequences encoding them, in which the ability of a serine residue to be phosphorylated is altered. In some aspects, the TSC2 serine residue cannot be phosphorylated (e.g., by substituting the serine residue with an alanine residue). In some aspects, the TSC2 serine acts as if it is constitutively phosphorylated (e.g., by substituting the serine residue with a glutamic acid residue). Also provided herein are engineered immune cells comprising altered TSC2 polypeptides or nucleic acid sequences encoding them, and methods of making and using such engineered immune cells.
    Type: Application
    Filed: July 13, 2018
    Publication date: May 14, 2020
    Inventors: David A. Kass, Mark J. Ranek, Kristen Kokkonen, Jonathan D. Powell, Chirag Patel
  • Patent number: 10525269
    Abstract: The invention provides methods related to improving heart function.
    Type: Grant
    Filed: November 22, 2016
    Date of Patent: January 7, 2020
    Assignee: THE JOHNS HOPKINS UNIVERSITY
    Inventors: David Kass, Gordon Tomaselli, Jonathan Kirk
  • Patent number: 10349695
    Abstract: An illuminable helmet assembly is disclosed. The helmet assembly may include a helmet body having an outer shell, an energy management layer and a fit system. A light diffuser is coupled to an outer surface of the helmet body, the diffuser having an illumination surface with an outer perimeter and defining a footprint of the illumination surface extending inward from the illumination surface to a center of the helmet body. A light source is positioned adjacent to and in some cases outside of the outer perimeter and the footprint of the illumination surface. The light source is positioned to emit light toward the illumination surface at an acute angle to the illumination surface.
    Type: Grant
    Filed: May 1, 2018
    Date of Patent: July 16, 2019
    Assignee: Bell Sports, Inc
    Inventors: David M. Thompson, Samuel Kass
  • Patent number: 10292980
    Abstract: In DN-DISC1 mice, a mouse model for major mental illnesses, the model that expresses pathological phenotypes relevant to schizophrenia, mood disorders, and addiction simultaneously, the inventors of the present invention found pronounced levels of oxidative stress in the prefrontal cortex, but not in the striatum. These mice also displayed greater amounts of GAPDH-Siah1 binding, a protein-protein interaction that is activated under exposure to oxidative stress. The present inventors investigated the role of oxidative stress in other organ systems. As detailed herein, the inventors found that GAPDH-Siah1 binding was increased in mouse models of cardiac failure. It was also found, that certain novel analogs of deprenyl, significantly inhibited GAPDH-Siah1 binding in cardiac tissue.
    Type: Grant
    Filed: December 12, 2016
    Date of Patent: May 21, 2019
    Assignee: THE JOHNS HOPKINS UNIVERSITY
    Inventors: Akira Sawa, Elki Takimoto, Neelam Shahani, David Kass, Toshiaki Saito
  • Publication number: 20180160917
    Abstract: The present application relates to systems and methods for non-invasively determining at least one of left ventricular end diastolic pressure (LVEDP) or pulmonary capillary wedge pressure (PCWP) in a subject's heart, comprising: receiving, by a computer, a plurality of signals from a plurality of non-invasive sensors that measure a plurality of physiological effects that are correlated with functioning of said subject's heart, said plurality of physiological effects including at least one signal correlated with left ventricular blood pressure and at least one signal correlated with timing of heartbeat cycles of said subject's heart; training a machine learning model on said computer using said plurality of signals for periods of time in which said plurality of signals were being generated during a heart failure event of said subject's heart; determining said LVEDP or PCWP using said machine learning model at a time subsequent to said training and subsequent to said heart failure event.
    Type: Application
    Filed: May 5, 2016
    Publication date: June 14, 2018
    Applicants: The Johns Hopkins University, Boston Scientific Scimed Inc.
    Inventors: Qian Liu, Nichaluk Leartprapun, Jackline Wanjala, Soumyadipta Acharya, Andrew Bicek, Viachaslau Barodka, Umang Anand, Majd Alghatrif, David Kass, B. Westbrook Bernier, Chao-Wei Hwang, Peter Johnston, Trent Langston
  • Publication number: 20170182321
    Abstract: The invention provides methods related to improving heart function.
    Type: Application
    Filed: November 22, 2016
    Publication date: June 29, 2017
    Inventors: David KASS, Gordon TOMASELLI, Jonathan KIRK
  • Publication number: 20170087145
    Abstract: In DN-DISC1 mice, a mouse model for major mental illnesses, the model that expresses pathological phenotypes relevant to schizophrenia, mood disorders, and addiction simultaneously, the inventors of the present invention found pronounced levels of oxidative stress in the prefrontal cortex, but not in the striatum. These mice also displayed greater amounts of GAPDH-Siah1 binding, a protein-protein interaction that is activated under exposure to oxidative stress. The present inventors investigated the role of oxidative stress in other organ systems. As detailed herein, the inventors found that GAPDH-Siah1 binding was increased in mouse models of cardiac failure. It was also found, that certain novel analogs of deprenyl, significantly inhibited GAPDH-Siah1 binding in cardiac tissue.
    Type: Application
    Filed: December 12, 2016
    Publication date: March 30, 2017
    Inventors: Akira Sawa, Elki Takimoto, Neelam Shahani, David Kass, Toshiaki Saito
  • Patent number: 9539427
    Abstract: The invention provides methods related to improving heart function.
    Type: Grant
    Filed: November 8, 2011
    Date of Patent: January 10, 2017
    Assignee: THE JOHNS HOPKINS UNIVERSITY
    Inventors: David Kass, Gordon Tomaselli, Jonathan Kirk
  • Publication number: 20160228460
    Abstract: Administration of an HNO/NO? donating compound, such as Angeli's salt, increases myocardial contractility while concomitantly lowering left ventricular preload in subjects experiencing heart failure. Moreover, administration of the HNO/NO? donating compound isopropylamine (IPA)/NO (Na(CH3)2CHNHN(O)NO) surprisingly exhibited positive inotropic effects in subjects experiencing heart failure that were superior to those caused by the HNO/NO? donating compound Angeli's salt. Additionally, in contrast to the effects observed with NO· donors, administration of an HNO/NO? donor in combination with a positive inotropic agent did not impair the positive inotropic effect of the positive inotropic agent. Further, HNO/NO? exerts its positive inotropic effect independent of the adrenergic system, increasing contractility even in subjects receiving beta-antagonist therapy.
    Type: Application
    Filed: April 20, 2016
    Publication date: August 11, 2016
    Inventors: David A. Wink, Martin Feelisch, David A. Kass, Nazareno Paolocci, Katrina Miranda, Jon Fukuto, Tatsuo Katori
  • Publication number: 20160166604
    Abstract: The present invention relates to methods for treating diastolic dysfunction or a disease, disorder or condition associated with diastolic dysfunction, methods for treating heart failure, methods for modulating SR Ca2+ release and/or uptake, methods for enhancing myocyte relaxation, preload or E2P hydrolysis, and methods for treating ventricular hypertrophy.
    Type: Application
    Filed: March 9, 2015
    Publication date: June 16, 2016
    Inventors: Nazareno Paolocci, David A. Kass, Carlo G. Tocchetti
  • Publication number: 20150218103
    Abstract: The present invention provides compounds and composition comprising analogs of deprenyl and their use in the inhibition of nuclear GAPDH-Siahl binding and the activation of p300 and MEF2. Also provided herein are methods of prevention and treatment of stress induced disorders of the body, including, for example, major mental illness, such as schizophrenia, mood disorders, and addiction, as well as stress-associated diseases involving other organs, such as cardiac hypertrophy, in vivo, comprising administering to a mammal a therapeutically effective amount of analogs of deprenyl.
    Type: Application
    Filed: August 19, 2013
    Publication date: August 6, 2015
    Inventors: Akira Sawa, Elki Takimoto, Neelam Shahani, David Kass, Toshiaki Saito
  • Publication number: 20150004259
    Abstract: Administration of an HNO/NO+ donating compound, such as Angeli's salt, increases myocardial contractility while concomitantly lowering left ventricular preload in subjects experiencing heart failure. Moreover, administration of the HNO/NO? donating compound isopropylamine (IPA)/NO (Na(CH3)2CHNHN(O)NO) surprisingly exhibited positive inotropic effects in subjects experiencing heart failure that were superior to those caused by the HNO/NO? donating compound Angeli's salt. Additionally, in contrast to the effects observed with NO? donors, administration of an HNO/NO? donor in combination with a positive inotropic agent did not impair the positive inotropic effect of the positive inotropic agent. Further, HNO/NO? exerts its positive inotropic effect independent of the adrenergic system, increasing contractility even in subjects receiving beta-antagonist therapy.
    Type: Application
    Filed: September 17, 2014
    Publication date: January 1, 2015
    Inventors: David A. Wink, Martin Feelisch, David A. Kass, Nazareno Paolocci, Katrina Miranda, Jon Fukuto, Tatsuo Katori
  • Publication number: 20130304149
    Abstract: The invention provides methods related to improving heart function.
    Type: Application
    Filed: November 8, 2011
    Publication date: November 14, 2013
    Inventors: David Kass, Gordon Tomaselli, Jonathan Kirk
  • Patent number: 8299083
    Abstract: The invention features methods and compositions featuring a PDE5 inhibitor for treating or preventing a cardiac indication in a subject.
    Type: Grant
    Filed: August 17, 2005
    Date of Patent: October 30, 2012
    Assignee: The Johns Hopkins University
    Inventors: David Kass, Eiki Takimoto, Hunter Champion
  • Patent number: 8268890
    Abstract: Nitroxyl donating compounds are administered prior to the onset of ischemia for the prevention and/or reduction of ischemia/reperfusion injury in subjects at risk for ischemia. Nitroxyl donors also are administered to organs to be transplanted for the prevention and/or reduction of ischemia/reperfusion injury upon reperfusion in a recipient. Nitroxyl donors include any nitroxyl donating compound. In particular cases the nitroxyl donor is a nitroxyl-donating diazeniumdiolate, such as Angeli's salt or IPA/NO.
    Type: Grant
    Filed: December 30, 2008
    Date of Patent: September 18, 2012
    Assignees: Johns Hopkins University, The United States of America as represented by the Secretary of Health and Human Services, The Regents of the University of California
    Inventors: David A. Wink, Martin Feelisch, Pasquale Pagliaro, David A. Kass, Nazareno Paolocci, Katrina M. Miranda, Jon M. Fukuto
  • Publication number: 20120201907
    Abstract: Administration of an HNO/NO? donating compound, such as Angeli's salt, increases myocardial contractility while concomitantly lowering left ventricular preload in subjects experiencing heart failure. Moreover, administration of the HNO/NO? donating compound isopropylamine (IPA)/NO (Na(CH3)2CHNHN(O)NO) surprisingly exhibited positive inotropic effects in subjects experiencing heart failure that were superior to those caused by the HNO/NO? donating compound Angeli's salt. Additionally, in contrast to the effects observed with NO donors, administration of an HNO/NO? donor in combination with a positive inotropic agent did not impair the positive inotropic effect of the positive inotropic agent. Further, HNO/NO? exerts its positive inotropic effect independent of the adrenergic system, increasing contractility even in subjects receiving beta-antagonist therapy.
    Type: Application
    Filed: April 13, 2012
    Publication date: August 9, 2012
    Applicants: The Board of Supervisors of Louisiana State University and Agricultural and Mechanical College, Johns Hopkins University, The Regents of the University of California, Government of the USA represented by the Secretary of the Department of Health and Human Services
    Inventors: David A. WINK, Martin FEELISCH, David A. KASS, Nazareno PAOLOCCI, Katrina MIRANDA, Jon FUKUTO, Tatsuo KATORI
  • Publication number: 20110263668
    Abstract: The present invention relates to the field of cardiology. More specifically, the present invention relates to the use of ?3 adrenoreceptor agonists to treat cardiac hypertrophy and heart failure. In a specific embodiment, a method for treating cardiac hypertrophy comprises the step of administering a therapeutically effective amount of a ?3 adrenoreceptor agonist to a patient diagnosed with cardiac hypertrophy. In a more specific embodiment, the method for treating cardiac hypertrophy comprises the step of administering a therapeutically effective amount of the ?3 adrenoreceptor agonist BRL 26830A to a patient diagnosed with cardiac hypertrophy. In a further embodiment, the present invention provides a method for treating a cardiovascular disease or condition associated with cardiac hypertrophy comprising the step of administering a therapeutically effective amount of a ?3 adrenoreceptor agonist to a patient diagnosed with cardiac hypertrophy.
    Type: Application
    Filed: July 1, 2010
    Publication date: October 27, 2011
    Applicant: THE JOHNS HOPKINS UNIVERSITY
    Inventors: Lili Ayala Barouch, David A. Kass, An L. Moens